

Please note the text space limits within the application fields. If you would like to provide images or figures, please submit one additional PDF page (optional Appendix) with your e-mail submission. All forms must be submitted by February 21, 2020. E-mail completed application form(s) to [NCISbirEvents@mail.nih.gov](mailto:NCISbirEvents@mail.nih.gov). Review "[Application Guide for Investor Initiatives](#)" for additional instructions.

By checking this box, I provide permission to share this application with non-federal investors and reviewers. (Please note that your application will be reviewed by an external panel of industry personnel and investment professionals. Only provide non-confidential data that can be shared with investors.)

NCI SBIR Grant or Contract Number for this product/technology: \_\_\_\_\_ (if you have multiple awards related to this technology/product, list the product you wish to be the focus of this application.)

NCI SBIR Program Director:    Christie Canaria    Greg Evans    Jonathan Franca-Koh    Kory Hallett    Nancy Kamei  
   Andrew Kurtz    Jian Lou    Deepa Narayanan    Monique Pond    Amir Rahbar  
   Ashim Subedee    Patricia Weber    Ming Zhao

**COMPANY INFORMATION**

Official Company Name: \_\_\_\_\_

Company Website: \_\_\_\_\_

Company Mailing Address: \_\_\_\_\_

Total Number Full-time Employees: \_\_\_\_\_ Total Number Part-time Employees: \_\_\_\_\_

Company CEO : \_\_\_\_\_

Phone: \_\_\_\_\_

E-mail: \_\_\_\_\_

Contact Person for this Application: \_\_\_\_\_

Title/Role: \_\_\_\_\_

Phone: \_\_\_\_\_

E-mail: \_\_\_\_\_

What year was the company founded: \_\_\_\_\_

Do you plan to apply for a Bridge Award in the next 12 months?     Yes     No     Bridge Recipient

**EXECUTIVE SUMMARY** (Please provide a short summary of your company & technology – limit 2400 characters at 9.5pt font)

## 1. TECHNOLOGY/PRODUCT OVERVIEW:

Type of Product/Technology: (Select **one** most relevant option)

- |  |  |   |
|--|--|---|
| <input type="checkbox"/> Small molecule              | <input type="checkbox"/> Biologics/Vaccine                       | <input type="checkbox"/> Cell/Gene therapy    |
| <input type="checkbox"/> Surgical or Ablative device | <input type="checkbox"/> Hospital device                         | <input type="checkbox"/> Drug delivery device |
| <input type="checkbox"/> Imaging device              | <input type="checkbox"/> Imaging agent                           |   |
| <input type="checkbox"/> In vitro diagnostic         | <input type="checkbox"/> Bioinformatics/Health IT/Digital health |   |
| <input type="checkbox"/> Research tool               |  |   |

Technology Description: (Please provide a short, one to three sentence, description of your technology)

### Current R&D Status:

- |  |  |  |                                    |
|--|--|--|------------------------------------|
| <input type="checkbox"/> V   |  |  |                                    |
| <input type="checkbox"/> Non-clinical technology in full development/testing stage |  |  |                                    |
| <input type="checkbox"/> Pre-clinical development                                  |  |  |                                    |
| <input type="checkbox"/> In clinical trials:                                       | <input type="checkbox"/> Phase I           | <input type="checkbox"/> Phase II          | <input type="checkbox"/> Phase III |
|  | <input type="checkbox"/> Early Feasibility | <input type="checkbox"/> Feasibility/Pilot | <input type="checkbox"/> Pivotal   |
| <input type="checkbox"/> Commercially available                                    |  |  |                                    |
| <input type="checkbox"/> Other (Please explain):                                   |  |  |                                    |

Technology/Product Overview Narrative. *Please describe the technology/product that was funded under the NCI SBIR program, its application, and "how it works." Include the current or potential impact of your product or technology on cancer patients, including the likelihood of clinical adoption and fit with existing practice. Limit your response to 3600 characters at 9.5pt font.) You may refer to any figures or images attached in the one-page appendix.*

## 2. SCIENTIFIC PROGRESS & STAGE OF DEVELOPMENT:

**FDA Application:**  PMA  510(k)  IDE  BLA  IND  NDA  Not applicable (no approval needed)  
**Current Status:**  Not yet submitted  Submitted  Approved  
**Reimbursement Planning:**  Not started reimbursement planning  Identification of CPT codes  Technology Add-ons  
 Insurance Coverage  CMS Processes  Other, (described in write-up below)

**Stage of Development Narrative.** *Please describe the current stage of development, major technical milestones achieved to date, and how they suggest clinical efficacy. Describe your progress toward the commercialization of the product and comment on how your product/prototype can be scalable and reproducible in a commercial environment. Also, please give a brief overview on the regulatory & reimbursement strategy for the product under development, including an update on current and imminent regulatory applications, approvals, and hurdles. Please limit your response to 2700 characters at 9.5pt font. You may refer to any figures or images to be included in the one-page Appendix PDF.*

## 3. MARKET DESCRIPTION AND PIPELINE PRODUCTS:

*Please describe the market for the product under development, providing market size and projected market growth, if available. Explain how your product fills a market niche and addresses an unmet need. Describe current and potential future commercial applications, including new products in development, and market segments. Limit 1600 characters at 9.5pt font.*

**4. COMPETITIVE ADVANTAGE:**

Please list/describe any unique attributes or competitive advantages the product has in the market over both current products and competing technologies under development. Limit 1600 characters at 9.5pt font.

**5. INTELLECTUAL PROPERTY:**

List any patent or patent applications. (Please enter numeric values where applicable. Feel free to expand on IP in your additional one page.)

Status (Filed, Provisional, Approved)	Number	Title	Date of Filing

List any invention reports, trademarks, or copyrights. (Please enter numeric values where applicable.)

	# Filed	# Approved	Subject matter or name of mark
Invention Reports			
Trademarks			
Copyrights			

**Intellectual Property Narrative.** Please describe the strength of your company's IP portfolio including issued patents, composition claims, and intellectual property licensed to the company (pertaining to this product) from academic or other institutions. List the patent title and numbers in the table below. Highlight your company's strategy to protect its IP. Limit 1500 Characters at 9.5pt font.

**6. PUBLICATIONS, PRESENTATIONS, AND AWARDS:**

*Please list the most significant past and pending publications, presentations, and awards based on the company's technology. Limit 1500 characters at 9.5pt font.*

**7. MANAGEMENT:**

Name, Title/Role	Domain expertise	Value Added/Previous Success

**Management Narrative.** *Describe the team or management structure, highlighting years of experience, background, and relevant previous success, experience, and domain expertise. You may provide additional information, as necessary. Limit 1500 characters at 9.5pt font.*

**8. BUSINESS DEVELOPMENT AND PARTNERSHIPS:**

Please list and specify any current or pending partnerships (e.g., strategic partner, licensing partner, manufacturing, distribution, technical collaboration, etc.) the company currently has related to the full commercialization of this product. Please also indicate what kind of partnerships you are seeking and the timing for seeking those partnerships. Please list company spin-offs, if any. Limit 1500 characters at 9.5pt font.

**9. FINANCIAL OVERVIEW:**

*Capital Raised to Date:* Please fill out the table below with information about capital that the company has raised since inception (include pre-incorporation awards, grants, private equity, venture capital, strategic partners, IPO, etc.):

Date	Type (grant, angel, venture, etc)	Source(s)	Amount	Additional Comments
8/2013	Series A	Generic Biotech Venture	\$3.5M	Example

**Financial Overview Narrative.** Describe funding received to develop your technology. List the revenue per year for the last 3 years. Also list projected revenue for the SBIR funded product/service (such as product revenues, consulting or licensing fees) and expected timeframes. How much funding are you currently seeking and what is your timeline for seeking funds? What do you plan to accomplish with these funds? Limit 1500 characters at 9.5pt font.

